News About: Pharm. Affairs
A series of launches of targeted antibodies has enlarged the patient selection
As a series of anticancer drugs targeting a specific disease has acquired product approvals, it is expected that patients will have a larger choice.
Recently, Ono Pharmaceutical Korea has acquired a product approval...
Xalkori is expected to exceed KRW 10 billion in the amount of claims for the first time of the year
The Pfizer Korea’s lung cancer treatment ‘Xalkori Cap(crizotinib)’ has been launched with the insurance benefit on the last 1st. It is expected that it will exceed KRW 14.5 billion in the first year’s claim amount due...
Will Pradaxa take the lead in the NOAC treatment market by the health insurance expansion?The insurance benefit range of the new oral anti-coagulant (NOAC) ‘Pradaxa(generic name: dabigatran)’ will be expanded from the 1st.
Through the expansion, the drug will not on...
|
The psoriasis treatment market will launch a large number of generics
Competition in the psoriasis treatment market is expected to be fierce.
This is because a number of generic products are looking forward to being launched in the KRW 12 billion psoriasis market which has been exclusi...
Large hospitals waiting for the launch of the new obesity drug ‘Belviq’
The new obesity drug, ‘Belviq,’ has been exceptionally noticeable among doctors.
Belviq has attracted doctors as a new obesity drug, which would be first launched since the last obesity drug in 13 years. Shinhan Inve...
GemVax and Samsung Pharm has launched its pancreatic cancer vaccine in Korea for the first time in the world
The GemVax’s pancreatic cancer vaccine, Liavax(code name: GV1001), has been acquired the final sale approval from the Ministry of Food and Drug Safety.
Liavax, a pharmaceutical product approved for the 21st time as ...
Expansion of the National Health Insurance benefits on chronic hepatitis type B and osteoporosis treatments from the coming 1st
Next month, the health insurance benefit of the tenofovir solo therapy will be applied to chronic hepatitis type B multiple drug resistance patients.
Moreover, osteoporosis treatments will be available with the healt...
Did the obesity treatment ‘Belviq’ become a blockbuster product in 2 months since its launch?
The Ildong Pharmaceutical’s ambitious work, Belviq, has been unveiled. As a result, the news was that it has recorded KRW 5.3 billion sales in 2 months since its launch. However, it seems to look into a little more ca...
“The Asian market is an industrial point,” domestic pharmaceutical companies paying attention in the reverse innovation
In order to target the Asian market, domestic pharmaceutical companies have accelerated their localization planning. The industry pays attention on the active localizing strategies, such as taking over foreign pharmac...
The KRW 600 billion antithrombotic industry is showing high interests in rapid growth of new products
Antithrombotic products, which have been 3 years since their launch, are energizing its depressed market through their rapid growth.
Particularly, Cilostan (Korea United Pharm) and Brilinta (AstraZeneca) have become ...
